Funding

Primrose Bio

United States · Biotech

Primrose Bio supplies manufacturing technologies for biologic drugs, mRNA products and vaccines.

Visit primrosebio.comFunding history

Product

Its portfolio includes the Pfenex microbial protein-production platform, Prima RNApols enzymes for mRNA manufacturing and PeliCRM197 carrier protein for conjugate vaccines.

Based in San Diego, Primrose works with pharmaceutical developers and manufacturers. Its technologies are used in marketed products as well as development programs.

Funding history

1 round · 0 with disclosed amounts
AnnouncedRoundAmountInvestors
Growth financingUndisclosedSignet Healthcare Partners — Lead1315 Capital — ParticipantAgent Capital — ParticipantLDV Partners — ParticipantLigand Pharmaceuticals — Participant

Investors

Signet Healthcare PartnersLed Growth financing1315 CapitalJoined Growth financingAgent CapitalJoined Growth financingLDV PartnersJoined Growth financingLigand PharmaceuticalsJoined Growth financing

Coverage

Sep 22, 2026Primrose Bio · Growth financing

Similar companies

Estuary BiotherapeuticsEstuary Biotherapeutics develops locally delivered gene therapies for patients with inherited polycystic kidney disease.$93M · Series A
OMass TherapeuticsOMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings.$310M · Series C
Soufflé TherapeuticsSoufflé Therapeutics develops targeted RNA medicines for patients with muscle disorders and heart failure.$135M · Series B
Sourcesprimrosebio.com ↗